In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:https://pubmed.ncbi.nlm.nih.gov/35803286/ 5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/35366963/ 6. Epcoritamab + R2 in high-risk follicular lymphoma:https://meetings.asco.org/abstracts-presentations/218265 7. Glofitamab in Mantle Cell Lymphoma:https://ashpublications.org/blood/article/140/Supplement%201/178/489039

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related